SGS Expands Phase I Trial Bed Capacity
SGS Life Science Services, a division of the SGS Group, has expanded its Phase I units in Antwerp Stuivenberg hospital (Belgium) by adding 22 new hospitalization beds. The clinical pharmacology unit brings the total number of beds to 102 for Belgium, and brings SGS's global capacity to 184 beds.
More information is available in the official Media Information document (PDF 28 KB):
SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, Bioanalytical and QC testing. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can favourably impact client's drug development timelines and decision-making.
For more information, please visit our website, www.sgs.com/CRO"
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
